Skip to main content
Journal cover image

Novel therapies for pancreatic adenocarcinoma.

Publication ,  Journal Article
Pino, SM; Xiong, HQ; McConkey, D; Abbruzzese, JL
Published in: Curr Oncol Rep
May 2004

Despite advances in our understanding of the molecular and genetic basis of pancreatic cancer, the disease remains a clinical challenge. Gemcitabine, the standard chemotherapy for pancreatic cancer, offers modest improvement of tumor-related symptoms and marginal advantage of survival. New approaches, alone and in combination with gemcitabine, are being developed to combat this cancer. In this article we review the current status of investigations into several classes of agents: matrix metalloproteinase inhibitors; farnesyl transferase inhibitors; epidermal growth factor receptor inhibitors, including monoclonal antibodies and tyrosine kinase inhibitors; cyclooxygenase-2 inhibitors, and others. The scientific rationale, mechanism of action, and clinical trial data for these novel agents are discussed.

Duke Scholars

Published In

Curr Oncol Rep

DOI

EISSN

1534-6269

Publication Date

May 2004

Volume

6

Issue

3

Start / End Page

199 / 206

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Protein-Tyrosine Kinases
  • Proteasome Inhibitors
  • Protease Inhibitors
  • Pancreatic Neoplasms
  • Oncology & Carcinogenesis
  • Oligonucleotides, Antisense
  • Matrix Metalloproteinase Inhibitors
  • Immunotherapy
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pino, S. M., Xiong, H. Q., McConkey, D., & Abbruzzese, J. L. (2004). Novel therapies for pancreatic adenocarcinoma. Curr Oncol Rep, 6(3), 199–206. https://doi.org/10.1007/s11912-004-0050-1
Pino, Simona M., Henry Q. Xiong, David McConkey, and James L. Abbruzzese. “Novel therapies for pancreatic adenocarcinoma.Curr Oncol Rep 6, no. 3 (May 2004): 199–206. https://doi.org/10.1007/s11912-004-0050-1.
Pino SM, Xiong HQ, McConkey D, Abbruzzese JL. Novel therapies for pancreatic adenocarcinoma. Curr Oncol Rep. 2004 May;6(3):199–206.
Pino, Simona M., et al. “Novel therapies for pancreatic adenocarcinoma.Curr Oncol Rep, vol. 6, no. 3, May 2004, pp. 199–206. Pubmed, doi:10.1007/s11912-004-0050-1.
Pino SM, Xiong HQ, McConkey D, Abbruzzese JL. Novel therapies for pancreatic adenocarcinoma. Curr Oncol Rep. 2004 May;6(3):199–206.
Journal cover image

Published In

Curr Oncol Rep

DOI

EISSN

1534-6269

Publication Date

May 2004

Volume

6

Issue

3

Start / End Page

199 / 206

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Protein-Tyrosine Kinases
  • Proteasome Inhibitors
  • Protease Inhibitors
  • Pancreatic Neoplasms
  • Oncology & Carcinogenesis
  • Oligonucleotides, Antisense
  • Matrix Metalloproteinase Inhibitors
  • Immunotherapy
  • Humans